Multinationals Start 2021 Empty Handed In China National Reimbursement Race
But Broader IO Indications An Advantage?
China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.